European Colorectal Cancer Screening and Diagnostics Market Analysis and Forecast 2023-2033, Featuring Key Companies Epigenomics, Mainz Biomed, Novigenics

European Colorectal Cancer Screening and Diagnostics Market

DUBLIN, March 7, 2024 (Globe Newswire) — The “European Colorectal Cancer Screening and Diagnostics Market: Analysis and Forecast, 2023-2033” report has been added. ResearchAndMarkets.com Recruitment.

European Colorectal Cancer Screening and Diagnostics Market was valued at $4.19 Billion in 2023 and is expected to reach $7.3 Billion by 2033, growing at 5.72 billion during the forecast period 2023-2033. Growing at a CAGR of %. The field of colorectal cancer screening and diagnosis is changing due to a variety of factors, including the increasing incidence of colorectal cancer, increasing financial burdens on health care systems, advances in genomics and molecular diagnostics, and the growing need for colorectal cancer testing. influenced by factors.

The European colorectal cancer screening and diagnostics market is experiencing significant growth due to several factors. The increasing incidence of colorectal cancer and the aging of the population have increased the demand for effective screening and diagnostic tools.

Additionally, increased awareness campaigns and government efforts to promote early detection are also contributing to market expansion. Advances in genomics and molecular diagnostics have improved the accuracy and efficiency of screening methods, further driving market growth.

Furthermore, the increasing financial burden on healthcare systems emphasizes the importance of cost-effective and efficient testing solutions. With the surge in demand for colorectal cancer testing, the European market is seeing notable developments in technology and innovation to meet evolving medical needs and improve patient outcomes.

Market segmentation:

Segmentation by type

Segmentation by end user

• hospitals and clinics

• clinical laboratory

• Other end users

Segmentation by country

• Germany

• France

• Italy

• England

• Spain

• Rest of Europe

Product/Innovation Strategy: This product segment helps readers understand how to screen and diagnose different types of colorectal cancer. Additionally, this study examines end-user applications (hospitals, clinics, clinical laboratories, and other end-users), types (blood-based tests, stool-based tests, colonoscopies, biomarker tests, and other tests). type), and region (Europe)

Growth/Marketing Strategy: The Colorectal Cancer Screening and Diagnostics market is witnessing significant developments such as business expansions, partnerships, collaborations, and new product launches by the key players operating in the market. The strategy favored by both companies was partnership and collaboration to strengthen their positions in the colorectal cancer screening and diagnostics market.

Competitive strategy: Key players in the colorectal cancer screening and diagnostics market analyzed and profiled in this study include leading colorectal cancer screening kit manufacturers (fecal DNA testing, FIT/FOB testing), biomarker testing kit manufacturers, sigmoid Includes mirrors, and colonoscope manufacturers. Additionally, detailed competitive benchmarking of players operating in the Colorectal Cancer Screening and Diagnostics market is carried out to help readers understand how the players compete with each other and provide a clear market picture. It has been.

story continues

Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations are expected to help readers understand the untapped revenue sources of the market.

Overview of key market players and competition

• epigenomics

• Mainz Biomed

• novigenics

Key attributes:

Main topics covered:

1 market
1.1 Market outlook
1.2 Industry Outlook
1.2.1 Regulatory framework
1.2.2 Redemption Scenario
1.2.2.1 Fecal immunochemical test/fecal occult blood test
1.2.2.2 Molecular testing
1.2.3 Patent analysis
1.2.4 Key trends
1.2.4.1 Rise of home colorectal cancer screening
1.2.4.2 Multidisciplinary approach to colorectal cancer screening
1.2.4.3 Use of gut microbiota in the diagnosis of colorectal cancer
1.2.5 Impact of the new coronavirus infection
1.2.6 Product Status
1.2.7 Product Pipeline
1.2.8 Business dynamics
1.2.8.1 Impact analysis
1.2.8.2 Business Drivers
1.2.8.2.1 Increasing incidence of colorectal cancer and increasing economic burden on health care
1.2.8.2.2 Advances in genomics and molecular diagnostics
1.2.8.2.3 Growing demand for colorectal cancer testing
1.2.8.2.4 Early detection of cancer enables reduction of treatment costs
1.2.8.3 Business Restrictions
1.2.8.3.1 Sensitivity limitations of FIT/FOBt test kits
1.2.8.3.2 Sample collection challenges
1.2.8.4 Business opportunities
1.2.8.4.1 Expansion of screening programs
1.2.8.4.2 Emerging markets suggest huge untapped potential

2 Colorectal cancer screening and diagnosis market (by region)
2.1 Europe
2.3 Company profile

• epigenomics

• Mainz Biomed

• novigenics

For more information on this report, please visit https://www.researchandmarkets.com/r/g806im.

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source of international market research reports and market data. We provide the latest data on international and regional markets, key industries, top companies, new products and latest trends.

attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900